Patients
NSCLC, non-small-cell lung cancer
ONCOLOGY, NSCLC
From December 2018 to November 2020, totally 60 patients were enrolled in this study; all of them received anlotinib plus icotinib at least once and were included in the SS and FAS (Table 
Baseline characteristics of the participantsData are presented as median (range) or n (%).ITT, intention-to-treat; EAS, efficacy analysis set; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small-cell lung cancer; EGFR, epidermal growth factor receptor gene.